Draftfcb buys New York pharma shop Hudson Global

Share this article:


Draftfcb Healthcare has bought Tarrytown, NY-based drug marketing shop Hudson Global.

The shop, founded in 2004, boasts a staff of 55 handling a roster of 20 clients in the pharma, diagnostic and biologics spaces. The agency will fall under the Draftfcb Healthcare umbrella but will continue to operate as a standalone unit under its old name and out of its Tarrytown office, led by its cofounders CEO/president Robert Blink and EVP Jason Goldklang. Blink will report to Draftfcb Healthcare and Draftfcb New York CEO Dana Maiman, and several employees will work regularly out of the network's Midtown Manhattan office (Tarrytown is around 25 miles north of Manhattan along the Hudson River).

Maiman praised the shop's expertise in medical education and sales training, along with its proprietary digital delivery technology, the SmartSeat platform, and exclusive video streaming partnership with MLB Advanced Media.

“It will enable tremendous video streaming and other proprietary technologies to be applied in the med ed and sales training areas,” said Maiman, adding that “We've been on the hunt for years and we wanted to acquire a company that had a very similar business approach and culture so that it would be seamless.”

Like Draftfcb Healthcare, said Maiman, “Their client roster spans blue chips to startups. They do such a broad array of programming – really diversified services, but they're better designed to answer specific business problems. They're extremely innovative and they'll drive revenue and sales for our clients' brands, and they're measure-able. That's why they're incredibly attractive and why they've been so successful.”

Interpublic Group's Draftfcb is among the giants of the healthcare marketing world, with not one but two conflict shops – NeON and Area 23 -- of its own.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...